Compare Google Inc (GOOG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Mesoblast Limited — how do they compare? Google Inc trades at $344.91 (market cap $4.20T), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: Google Inc is far larger — about 1900.5× Mesoblast Limited's market cap, and Google Inc pays a 0.26% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GOOG | MESO | |
|---|---|---|
Market Cap | $4.20T | $2.21B |
Volume | 1,511,127 | — |
Sector | Technology | Technology |
52-Week High | $399.06 | $20.96 |
52-Week Low | $200.19 | $12.88 |
Enterprise Value | $4.09T | $2.21B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $355.84, up 0.67% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion, and announced a new AI leadership structure to accelerate Gemini development amid rising user adoption.
Outlook remains positive with an 86.84% analyst buy rating and a $431.67 consensus price target, though risks include high capital expenditure for AI infrastructure and regulatory scrutiny. The stock offers growth potential from AI monetization but faces volatility from tech sector pressures and antitrust investigations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
